Racura Oncology (ASX:RAC): September Quarter Cash and RC220 Trial Progress

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Racura Oncology (ASX:RAC): September Quarter Cash and RC220 Trial Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Racura Oncology (ASX:RAC) held AUD 30.74mn in cash and cash equivalents at 30 September 2026.
The company reported approximately AUD 2.46mn of expenditure on research, development and drug manufacturing during the quarter.
HARNESS-1 advanced to a 100 mg/m² RC220 dose level following safety review of its initial cohort.
The CPACS Phase 1 trial expanded into South Korea and continued enrolling patients in multiple jurisdictions.

Racura Oncology Limited (ASX:RAC) is a clinical-stage biopharmaceutical company developing RC220, a formulation of bisantrene being studied in several cancer-treatment settings. After the trading session ended on 26 October 2026, Racura Oncology (ASX:RAC) shares closed at AUD 1.63, up 2.84% for the day. Its latest quarterly update describes progress in two early-stage combination-treatment trials, continued recruitment activity and the cash resources available to support further clinical development.

Company Business

Racura Oncology (ASX:RAC) researches anticancer applications of RC220, including combinations with established cancer medicines. The development program is directed toward testing the safety, dosing and potential therapeutic effects of the compound in defined patient populations. The company is not operating a broad commercial medicine-sales business; clinical trial progress and access to development funding are therefore central to its operating activities.

The HARNESS-1 Phase 1a/b trial evaluates RC220 together with osimertinib in patients with EGFR-mutated non-small cell lung cancer. The CPACS Phase 1 study tests RC220 alongside doxorubicin in patients with advanced solid tumours. Racura Oncology (ASX:RAC) is also pursuing a program involving relapsed or refractory acute myeloid leukaemia, with development plans subject to trial execution and regulatory processes.

Recent Development

In its 22 October 2026 September-quarter report, Racura Oncology (ASX:RAC) said the initial HARNESS-1 combination-treatment cohort had progressed through safety assessment. In July, an initial patient completed the observation period without a dose-limiting toxicity or treatment-related safety concern, after which the trial continued with an additional patient at the same dose.

On 12 October, the company reported that its safety review committee had cleared escalation to the next planned RC220 dose level of 100 mg/m². Both patients assessed at 50 mg/m² had completed the relevant review without dose-limiting toxicities. This was an early safety milestone rather than evidence that the treatment combination improves clinical outcomes.

The CPACS trial expanded geographically in September when its first South Korean clinical site was activated. An October clinical update reported that the initial dose cohort had been completed without dose-limiting toxicities and that recruitment was continuing in Australia, Hong Kong and South Korea. Additional Australian ethics approvals also supported preparations for further HARNESS-1 sites in New South Wales and Victoria.

Financial Performance and Sector Context

At 30 September 2026, Racura Oncology (ASX:RAC) reported cash and cash equivalents of AUD 30.74mn. The quarterly report stated that about 80% of the relevant operating spend, equivalent to approximately AUD 2.46mn, was allocated to research and development and drug manufacturing. This expenditure profile reflects the company’s focus on clinical studies and the supply of investigational medicines.

Management indicated that the reported cash balance was expected to support committed activities into mid-calendar 2028. That outlook is linked to its planned development program and expenditure assumptions, while additional studies, changes in recruitment timelines or expanded manufacturing requirements could affect future funding needs. The September-quarter disclosure also recorded AUD 0.199mn of payments to related parties, covering executive remuneration and non-executive director fees.

For oncology developers at Racura’s stage, quarterly cash balances, trial costs and regulatory milestones can be more informative than conventional product-sales measures. The company’s near-term operating assessment consequently centres on clinical execution, capital allocation and whether emerging safety findings allow studies to proceed to subsequent dose cohorts.

Risks to Consider

Racura Oncology (ASX:RAC) remains exposed to uncertainty over trial safety, drug efficacy, patient recruitment and regulatory assessment. Early dose-cohort clearance does not establish that a candidate will meet later clinical endpoints. Further expenditure may be required if trials are extended or programs expand. The company also faces manufacturing, site activation and financing risks, while future commercial agreements depend on counterparties and satisfactory clinical evidence.

What to Watch Next

The next reported developments for Racura Oncology (ASX:RAC) include enrolment and safety review at the higher HARNESS-1 dose, subsequent CPACS dose cohorts and recruitment across participating clinical sites. Investors can also monitor updates concerning the acute myeloid leukaemia program, quarterly operating cash outflows and any formal changes to clinical timelines. The annual general meeting was scheduled for 23 November 2026.

Key Insights

Racura Oncology (ASX:RAC) ended September with AUD 30.74mn in cash as its RC220 program advanced through early clinical safety milestones. HARNESS-1 received clearance for dose escalation, while CPACS added a South Korean trial site. Subsequent safety observations, patient recruitment, trial expenditure and potential development arrangements will determine the next measurable changes in the company’s clinical program.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.